Article thumbnail

Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review

By Marni Jacobs, Natasha Nassar, Christine L Roberts, Ruth Hadfield, Jonathan M Morris and Anthony W Ashton


Angiogenic factors are involved in formation of new blood vessels required for placental development and function; and critical for fetal growth and development. Soluble fms-like tyrosine kinase 1(sFlt-1) is an anti-angiogenic protein that inhibits formation of new blood vessels resulting in potential pregnancy complications. The objective of this study was to undertake a systematic review to assess levels of sFlt-1 in early pregnancy and association with adverse pregnancy outcomes. PubMed and Medline databases and reference lists were searched up to July 2010. Inclusion criteria were pregnant women, blood sample taken during first trimester and assessment/reporting of sFlt-1 concentrations and subsequent pregnancy complications. Twelve relevant studies were identified of 71 to 668 women. No pooling of results was undertaken due to variation in sFlt-1 concentrations (range, 166-6,349 pg/ml amongst controls), samples used (serum, plasma), different summary statistics (mean, median, odds ratio) and outcome definitions applied. Levels of sFlt-1 were generally higher among women who developed preeclampsia (11 studies) or gestational hypertension (two studies), but not significantly different to normotensive women in most studies. There was no consistent pattern in association between sFlt-1 concentrations and fetal growth restriction (4 studies); and levels were non-significantly higher for women with postpartum bleeding (1 study) and significantly lower for stillbirths (1 study).This review found no clear evidence of an association between sFlt-1 levels in first trimester and adverse pregnancy outcomes. However, findings were affected by methodological, biological and testing variations between studies; highlighting the need for consistent testing of new biomarkers and reporting of outcome measures

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1993). A: All MoMs are not equal: some statistical properties associated with reporting results in the form of multiples of the median.
  2. (2007). AC: Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia.
  3. (2004). al: Circulating angiogenic factors and the risk of preeclampsia.
  4. (2004). Aspects of human fetoplacental vasculogenesis and angiogenesis. III. Changes in complicated pregnancies. Placenta
  5. (2005). Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension
  6. (2002). Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn
  7. (2010). DJ: Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation
  8. (2007). Dobbie R: Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol
  9. (2008). eds: Cochrane handbook for systematic reviews of interventions.
  10. (2003). et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
  11. (2005). et al: Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia.
  12. (2008). et al: The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.
  13. (2010). Holers VM: The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG
  14. (2004). Karumanchi SA: First trimester placental growth factor and soluble fmslike tyrosine kinase 1 and risk for preeclampsia.
  15. (2010). KH: Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat Diagn
  16. (2006). KH: Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction.
  17. (2010). Lancet
  18. (2009). Lapaire O: Potential markers of preeclampsia–a review. Reprod Biol Endocrinol
  19. (2008). Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia.
  20. (2006). Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation.
  21. (2008). PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand
  22. (2008). Predictors and risk factors of pre-eclampsia. Minerva Ginecol
  23. (2005). RB: Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia.
  24. (2006). RJ: Circulating angiogenic factors and placental abruption. Obstet Gynecol
  25. (2004). Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop.
  26. (2008). Surbek DV: First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
  27. (2007). Surbek DV: Serum markers for predicting preeclampsia. Mol Aspects Med
  28. (2007). Thadhani R: Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension
  29. (2008). Vatten LJ: Levels of angiogenic factors in pregnancy and post-partum bleeding. Acta Obstet Gynecol Scand
  30. (2008). VD: Vasculogenesis and angiogenesis in the IUGR placenta. Semin Perinatol
  31. (2007). Ylikorkala O: Failure of second-trimester measurement of soluble endoglin and other angiogenic factors to predict placental abruption. Prenat Diagn